These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 20205098)

  • 1. Serum endostatin levels in patients with metastatic and non-metastatic well-differentiated thyroid cancer.
    Kłubo-Gwieździńska J; Junik R; Kopczyńska E
    Endokrynol Pol; 2010; 61(1):7-12. PubMed ID: 20205098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation.
    Tuttle RM; Fleisher M; Francis GL; Robbins RJ
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1737-42. PubMed ID: 11932308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and secretion of endostatin in thyroid cancer.
    Hoffmann S; Wunderlich A; Lingelbach S; Musholt PB; Musholt TJ; von Wasielewski R; Zielke A
    Ann Surg Oncol; 2008 Dec; 15(12):3601-8. PubMed ID: 18818971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum soluble interleukin 2 (IL-2) receptor (sIL-2R) in differentiated thyroid carcinoma.
    Mariotti S; Barbesino G; Caturegli P; Marinò M; Manetti L; Fugazzola L; Pacini F; Pinchera A
    J Endocrinol Invest; 1994 Dec; 17(11):861-7. PubMed ID: 7745234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The comparison of serum vascular endothelial growth factor levels between patients with metastatic and non-metastatic thyroid cancer, and patients with nontoxic multinodular goiter.
    Klubo-Gwiezdzinska J; Junik R; Kopczynska E; Juraniec O; Kardymowicz H
    Eur J Endocrinol; 2007 Oct; 157(4):521-7. PubMed ID: 17893268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal metastasis from papillary thyroid microcarcinoma.
    Liou MJ; Lin JD; Chung MH; Liau CT; Hsueh C
    Acta Otolaryngol; 2005 Apr; 125(4):438-42. PubMed ID: 15823819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases.
    Lin JD; Huang MJ; Juang JH; Chao TC; Huang BY; Chen KW; Chen JY; Li KL; Chen JF; Ho YS
    Thyroid; 1999 Dec; 9(12):1227-35. PubMed ID: 10646663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group.
    Schips L; Dalpiaz O; Lipsky K; Langner C; Rehak P; Puerstner P; Pummer K; Zigeuner R
    Eur Urol; 2007 Jan; 51(1):168-73; discussion 174. PubMed ID: 16844285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment serum endostatin as a prognostic indicator in metastatic gastric carcinoma.
    Woo IS; Kim KA; Jeon HM; Hong SH; Rho SY; Koh SJ; Lee MA; Byun JH; Kang JH; Hong YS; Lee KS; Cho CS; Choi MG; Chung IS
    Int J Cancer; 2006 Dec; 119(12):2901-6. PubMed ID: 16998835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer.
    Lima N; Cavaliere H; Tomimori E; Knobel M; Medeiros-Neto G
    J Endocrinol Invest; 2002 Feb; 25(2):110-5. PubMed ID: 11929080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The early treatment results of well differentiated thyroid cancer and its dependence on chosen factors].
    Kłubo-Gwieździńska J; Junik R
    Endokrynol Pol; 2008; 59(2):123-30. PubMed ID: 18465687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer.
    Feldman AL; Tamarkin L; Paciotti GF; Simpson BW; Linehan WM; Yang JC; Fogler WE; Turner EM; Alexander HR; Libutti SK
    Clin Cancer Res; 2000 Dec; 6(12):4628-34. PubMed ID: 11156212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Clinical Research of Serum VEGF, TGF-β1, and Endostatin in Non-small Cell Lung Cancer.
    Liu SG; Yuan SH; Wu HY; Liu J; Huang CS
    Cell Biochem Biophys; 2015 May; 72(1):165-9. PubMed ID: 25548002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical significance of serum levels of endostatin in patients with clear cell renal cell carcinoma].
    Guan KP; Xiao ZD; Wang D; Shi HZ; Guan YY; Lu L; Han SJ; Li CL
    Zhonghua Wai Ke Za Zhi; 2009 May; 47(10):737-9. PubMed ID: 19615205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial Size of Metastatic Lesions Is Best Prognostic Factor in Patients with Metastatic Differentiated Thyroid Carcinoma Confined to the Lung.
    Kim M; Kim WG; Park S; Kwon H; Jeon MJ; Lee JJ; Ryu JS; Kim TY; Shong YK; Kim WB
    Thyroid; 2017 Jan; 27(1):49-58. PubMed ID: 27750021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lung metastases in patients with differentiated thyroid carcinoma and evaluation of response to radioiodine therapy.
    Kalender E; Zeki Celen Y; Elboga U; Deniz Demir H; Yilmaz M
    Rev Esp Med Nucl Imagen Mol; 2012; 31(6):328-31. PubMed ID: 23084016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy.
    de Keizer B; Brans B; Hoekstra A; Zelissen PM; Koppeschaar HP; Lips CJ; van Rijk PP; Dierckx RA; de Klerk JM
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):367-73. PubMed ID: 12634964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin.
    Malandrino P; Latina A; Marescalco S; Spadaro A; Regalbuto C; Fulco RA; Scollo C; Vigneri R; Pellegriti G
    J Clin Endocrinol Metab; 2011 Jun; 96(6):1703-9. PubMed ID: 21450986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Correlation of pretreatment serum level of endostatin to posttreatment distant metastasis in patients with advanced nasopharyngeal carcinoma].
    Zhao ZJ; Mo HY; Zhang CQ; Qi B; Li J; Hong MH; Mai HQ
    Ai Zheng; 2007 Nov; 26(11):1243-7. PubMed ID: 17991326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry.
    Cooper DS; Specker B; Ho M; Sperling M; Ladenson PW; Ross DS; Ain KB; Bigos ST; Brierley JD; Haugen BR; Klein I; Robbins J; Sherman SI; Taylor T; Maxon HR
    Thyroid; 1998 Sep; 8(9):737-44. PubMed ID: 9777742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.